About Atmo Biosciences
Atmo Biosciences is a company based in Melbourne (Australia) founded in 2017. Atmo Biosciences has raised $7.01 million across 4 funding rounds from investors including Otsuka and Breakthrough Victoria. Atmo Biosciences offers products and services including Atmo Gas Capsule. Atmo Biosciences operates in a competitive market with competitors including Roche, EKF, SonoSite, Cordant Health Solutions and NVision Imaging Technologies, among others.
- Headquarter Melbourne, Australia
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.01 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
Otsuka
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Atmo Biosciences
Atmo Biosciences offers a comprehensive portfolio of products and services, including Atmo Gas Capsule.
Ingestible capsule measures gases for gastrointestinal transit evaluation.
People of Atmo Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Atmo Biosciences
Atmo Biosciences has successfully raised a total of $7.01M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Atmo Biosciences
Atmo Biosciences has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Otsuka and Breakthrough Victoria.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Breakthrough Victoria is focused on investing in innovation for economic growth.
|
Locked | Locked | Locked | |
|
Generic pharmaceuticals and nutraceuticals are manufactured and marketed by Otsuka.
|
Locked | Locked | Locked |
Investor details for Atmo Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Atmo Biosciences
Investment portfolio details for Atmo Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Atmo Biosciences
Detailed financials for Atmo Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Atmo Biosciences Comparisons
Peer comparison for Atmo Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Atmo Biosciences
Atmo Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Roche, EKF, SonoSite, Cordant Health Solutions and NVision Imaging Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
|
| Locked | Locked | Locked |
Point-of-care and laboratory blood analyzers are developed by EKF.
|
|
| Locked | Locked | Locked |
Hand-carried ultrasound systems for medical specialties are developed and distributed.
|
|
| Locked | Locked | Locked |
Drug testing services are offered for clinical trials and workplaces.
|
|
| Locked | Locked | Locked |
Medical imaging is provided through quantum technologies.
|
|
| Locked | Locked | Locked |
Cloud based diagnostics platform for point of care diagnosing
|
Detailed competitors of Atmo Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Atmo Biosciences
Complete news archive for Atmo Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atmo Biosciences
Atmo Biosciences was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Atmo Biosciences is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Malcolm Hebblewhite is the current CEO of Atmo Biosciences.
Atmo Biosciences is a funded company, having raised a total of $7.01M across 4 funding rounds to date.
Atmo Biosciences was founded in 2017 as a spinoff of RMIT University in Melbourne, Australia. The company focuses on commercializing a swallowable gas sensor for monitoring intestinal gases including hydrogen, carbon dioxide, and oxygen. Data is transmitted wirelessly to a smartphone. A partnership with Planet Innovation supports development of the technology as a diagnostic tool for gut disorders such as nutrient malabsorption and colon cancer. Operations are based in Melbourne.
Atmo Biosciences offers Atmo Gas Capsule.
Atmo Biosciences has 2 investors. Key investors include Otsuka, and Breakthrough Victoria.